MedTrace Logo

DOAC ADRs Retrospective Study

NCT04247919 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 3

Last updated 2021-03-08

No results posted yet for this study

Summary

This retrospective study's objective is to evaluate if Cipherome's algorithm could have predicted the serious adverse drug reactions (ADRs) experienced by patients while on direct oral anti-coagulants (DOACs).

Conditions

  • Drug-Related Side Effects and Adverse Reactions

Sponsors & Collaborators

  • Santa Clara Valley Medical Center

    collaborator OTHER

  • Cipherome, Inc.

    lead INDUSTRY

Principal Investigators

  • Clifford Wang, MD · Santa Clara Valley Medical Center

  • Michelle Wilson, MD · Santa Clara Valley Medical Center

  • Jessica Song, PharmD · Santa Clara Valley Medical Center

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-01-10
Primary Completion
2020-07-24
Completion
2020-07-24

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04247919 on ClinicalTrials.gov